Drug intelligence / Profile preview

rosastat

Development stage: Preclinical
Lead developer: AstraZeneca
Administration: Oral, Nasogastric Tube, Intravenous

Overview

Rosastat is a pharmaceutical agent currently under investigation for its potential in treating renal anemia, particularly in patients experiencing inflammatory states. Its efficacy is being evaluated in a retrospective clinical study.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on rosastat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosastat.

Explore the full profile